Skip to main content
. Author manuscript; available in PMC: 2013 Aug 15.
Published in final edited form as: J Immunol. 2012 Jul 16;189(4):1983–1991. doi: 10.4049/jimmunol.1101665

FIGURE 1.

FIGURE 1

RvD1 decreases allergic lung inflammation. (A). Mice were sensitized and challenged with OVA prior to one dose of RvD1 (10 ng, i.v.) or vehicle 1 hour before BAL on protocol day 18 (inset). Total leukocytes and leukocyte subsets were enumerated (see Methods). (B) A second cohort of sensitized and challenged mice received RvD1 (1–100 ng, i.v.) or vehicle 30 minutes prior to OVA aerosol challenge on 4 successive days (protocol days 14–17) (inset) and BALF leukocytes were enumerated on protocol day 18. The dashed black line indicates the cells from OVA naïve, non-allergic control mice. Results represent the mean ± s.e.m of two or more independent experiments with three or more mice per group per experiment. * P < 0.05 vs. vehicle.